Document Detail


Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: Results from a pilot phase 2 study.
MedLine Citation:
PMID:  20671417     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
OBJECTIVE: Current therapies for acromegaly are unsatisfactory for some patients. High-dose thiazolidinediones have been reported to reduce serum GH levels in animal models of acromegaly. The objective of the study was to evaluate the effect of increasing doses of rosiglitazone on serum GH and IGF-I concentrations in acromegalic patients.
DESIGN: Phase 2 clinical trial.
PATIENTS AND METHODS: Five consecutive patients with active and uncontrolled acromegaly under conventional medical therapies were treated with increasing doses of rosiglitazone [4 mg/day every month, starting from 8 up to 20 mg/day] added to previous medical therapies for acromegaly.
RESULTS: Mean serum IGF-I concentrations decreased from 547±91 to 265±126 μg/l (p<0,001) during rosiglitazone treatment: 4 patients had normal serum IGF-I concentrations, and a patient had lowered serum IGF-I values, although still abnormal, at the end of the study. On the contrary, serum GH concentrations did not significantly changed during rosiglitazone therapy as well as other pituitary hormones. No relevant side effects of rosiglitazone were observed during the study period. Quantitative real time PCR and Western blotting showed that rosiglitazone lowered GH-dependent hepatic generation of IGF-I in HepG2 cell line.
CONCLUSIONS: Rosiglitazone reduces serum IGF-I concentrations in patients with uncontrolled acromegaly under conventional medical therapies, likely acting on the GH-dependent hepatic synthesis of IGF-I. Large studies are necessary to confirm the role of rosiglitazone as an adjunctive therapy for uncontrolled acromegalic patients under conventional medical therapies.
Authors:
F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Related Documents :
12721507 - Somatostatin analogs in medical treatment of acromegaly.
17785357 - Growth hormone replacement improves thyroxine biological effects: implications for mana...
7708377 - Analytical methods for evaluating episodic secretory activity within neuroendocrine axes.
2205627 - Assessment of growth hormone secretion in normal stature children using 24-hour integra...
17291597 - Smelling lavender and rosemary increases free radical scavenging activity and decreases...
23804777 - Postoperative serum cortisol concentration and adrenal insufficiency in neonates underg...
Publication Detail:
Type:  Journal Article     Date:  2010-07-29
Journal Detail:
Title:  Journal of endocrinological investigation     Volume:  34     ISSN:  1720-8386     ISO Abbreviation:  J. Endocrinol. Invest.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-04-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7806594     Medline TA:  J Endocrinol Invest     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  e43-51     Citation Subset:  IM    
Affiliation:
Department of Endocrinology and Metabolism, University of Pisa, Via Paradisa 2, 56124 Pisa, Italy. fausto.bogazzi@med.unipi.it.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Resistin level is positively correlated with thrombotic complications in Southern Chinese metabolic ...
Next Document:  Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subj...